News

Fierce Pharma16h
With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
Sanofi finds M&A fix for its multiple itches
The French drugmaker will pay up to $9.5 bln for Blueprint Medicines, whose key product fights skin rashes. It eases CEO Paul ...
The Express Tribune14h
Sanofi makes biggest European pharma deal of 2025 with Blueprint purchase
Sanofi agrees to buy Blueprint Medicines for $9.5 billion, enhancing its rare disease treatments and immunology drug pipeline ...
Sanofi announces major purchase amid pledge to up U.S. investments
Global healthcare company Sanofi, headquartered in Paris, France, is announcing another pricey purchase in the U.S.
Fierce Biotech18h
Sanofi pays $15M for another STAT6 degrader from fruitful Nurix collab
Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...
Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover
French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for $9.5 billion, sending shares of the ...
Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment
Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on ...
Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials
Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...